The content of this website is intended for healthcare professionals only

Loading
Loading...

Go-ahead for trials using human embryonic stem cells

Jo Carlowe

Friday, 23 September 2011

Add to PDP Tracker

A UK hospital has been given permission to carry out Europe’s first clinical trial using human embryonic stem cells.

The Medicines and Healthcare Products Regulatory Agency (MHRA) gave Moorfields Eye Hospital approval to trial an experimental new treatment using retinal cells derived from stem cells to treat people with advanced Stargardt disease, a form of macular degeneration that causes disabling loss of sight in young people.

The cells will be injected into the retina during an operation lasting up to an hour.

“There is real potential that people with blinding disorders of the retina, including Stargardt disease and age-related macular degeneration, might benefit in the future from transplantation of retinal cells,” says retinal surgeon Professor James Bainbridge, who will be conducting the trials at the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields and the UCL Institute of Ophthalmology.

“The ability to regenerate retinal cells from stem cells in the laboratory has been a significant advance and the opportunity to help translate such technology into new treatments for patients is hugely exciting. Testing the safety of retinal cell transplantation in this clinical trial will be an important step towards achieving this aim.”

“We are delighted to be the site for these very exciting new clinical trials in stem cell therapy, which have the potential to give hope and make such a difference to the lives of people with currently untreatable blinding retinal conditions”, adds Professor Peng Khaw, director of the biomedical research centre at Moorfields. 

“It is crucial that we continue to attract external investment for world-leading research in the UK, through the NIHR’s transformational investment in research infrastructure through national biomedical research centres such as ours here at Moorfields and the UCL Institute of Ophthalmology. " 

The technology has been developed by US company Advanced Cell Technology (ACT), who got the go ahead to run similar trials in the United States in November 2010.

201306 - Binleys map banner
Wilmington Healthcare Limited, 6-14 Underwood Street, London, England, N1 7JQ
Copyright 2013 Wilmington Healthcare Limited
Registered in England and Wales, Reg No. 2530185
Twitter   Facebook
A Wilmington Company